MA
NBSE

MYDA Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

MYDA Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,250
Closed -$333K – 356
2021
Q1 		$333K Buy
+2,250
New +$408K 0.09% 215

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MYDA Advisors's NBSE Position: Q2 2021 in Review

MYDA Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2021, closing a stake of 2,250 shares — an estimated $333K sold.

MYDA Advisors first reported a position in NBSE in Q1 2021 and held it in 1 quarter. The position peaked at $333K in Q1 2021. 57 funds tracked by Wall St. Rank hold NBSE as of Q2 2021.

  • MYDA Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • MYDA Advisors sold 2,250 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $333K.
  • MYDA Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • MYDA Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $333K in Q1 2021.
  • 57 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2021.

Based on MYDA Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.